Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486173 | 0.82 | SMN1; SMN2 (0.47) | KMT2APOLBHTTRAB9ANPC1 | |
| SCHEMBL2483553 | 0.80 | POLB (0.32) | KMT2APOLBKDM4ECHRNB2CHRNB4 | |
| SCHEMBL5404611 | 0.80 | PLAU (0.33) | KMT2APOLBKDM4ECHRNB2CHRNB4 | |
| SCHEMBL455438 | 0.78 | KMT2A (0.53) | KMT2APOLBKDM4EHTTFAAH | |
| SCHEMBL482526 | 0.78 | KMT2A (0.59) | KMT2APOLBKDM4EHTTRAB9A | |
| SCHEMBL5516357 | 0.77 | KMT2A (0.38) | KMT2ARAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL9490747 | 0.77 | ROCK2 (0.47) | KDM4EHTTRAB9ANPC1PKM | |
| SCHEMBL2535672 | 0.77 | PGR (0.41) | KMT2ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL6788749 | 0.76 | KMT2A (0.52) | KMT2APOLBKDM4EHTTFAAH | |
| SCHEMBL11788282 | 0.76 | HDAC1 (0.44) | KMT2APOLBKDM4ERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2019-07-25 | — | — | US | claimed |
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | claimed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | claimed |
| US-10233182-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180282332-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2018-10-04 | — | — | US | disclosed |
| CN-107106559-A | Substituted spirocyclic inhibitors of autotaxin | X-RX股份有限公司 | 2017-08-29 | — | — | CN | disclosed |
| EP-3125895-A1 | SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN | X-RX, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | disclosed |
| WO-2015154023-A1 | SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN | X-RX DISCOVERY, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| US-6794372-B2 | QUINOLONE ANTIBIOTIC VIRICIDES, FUNGICIDES, AND BACTERICIDES | NICOX S.A. (FR) | 2004-09-21 | — | — | US | disclosed |
| US-20040072798-A1 | Compositions comprising cyclodextrins and no-releasing drugs | NICOX S.A. (FR) | 2004-04-15 | — | — | US | disclosed |
| EP-1347782-A1 | COMPOSITIONS COMPRISING CYCLODEXTRINS AND NO-RELEASING DRUGS | Nicox S.A. (FR) | 2003-10-01 | — | — | EP | disclosed |
| US-20030105066-A1 | Nitrate salts of antimicrobial agents | NICOX S.A. (FR) | 2003-06-05 | — | — | US | disclosed |
| WO-2002053188-A1 | COMPOSITIONS COMPRISING CYCLODEXTRINS AND NO-RELEASING DRUGS | NICOX S.A. (FR) | 2002-07-11 | — | — | WO | disclosed |
| EP-1219306-A1 | Compositions comprising cyclodextrins and NO- releasing drugs | NICOX S.A. (FR) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072798-A1 | Compositions comprising cyclodextrins and no-releasing drugs | NOS1, NOS2, NOS3 | KMT2A 4744/4885POLB 4331/4885KDM4E 4029/4885 |
| US-10233182-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, CXCR3, SLC10A1 | KMT2A 2582/4885POLB 3957/4885KDM4E 3789/4885 |
| US-20180282332-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, CXCR3, SLC10A1 | KMT2A 2582/4885POLB 3957/4885KDM4E 3789/4885 |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | PDE2A, PDE3B, PDE3A | KMT2A 1978/4885POLB 871/4885KDM4E 1186/4885 |
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, SLC10A1, CXCR3 | KMT2A 2521/4885POLB 4040/4885KDM4E 3762/4885 |
| US-20030105066-A1 | Nitrate salts of antimicrobial agents | NOS1, NOS3, NOS2 | KMT2A 4620/4885POLB 575/4885KDM4E 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.